NASDAQ:ONCT Oncternal Therapeutics (ONCT) Stock Price, News & Analysis → No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (From Hedgeye) (Ad) Free ONCT Stock Alerts $8.39 -0.60 (-6.67%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$8.16▼$8.6750-Day Range$8.00▼$9.4152-Week Range$5.57▼$13.14Volume7,370 shsAverage Volume10,260 shsMarket Capitalization$24.83 millionP/E RatioN/ADividend YieldN/APrice Target$28.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Oncternal Therapeutics alerts: Email Address Oncternal Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside237.7% Upside$28.33 Price TargetShort InterestHealthy0.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$86,281 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($10.78) to ($10.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.22 out of 5 starsMedical Sector490th out of 905 stocksPharmaceutical Preparations Industry232nd out of 430 stocks 3.3 Analyst's Opinion Consensus RatingOncternal Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOncternal Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Oncternal Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.87% of the float of Oncternal Therapeutics has been sold short.Short Interest Ratio / Days to CoverOncternal Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncternal Therapeutics has recently increased by 77.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOncternal Therapeutics does not currently pay a dividend.Dividend GrowthOncternal Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONCT. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Oncternal Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for ONCT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Oncternal Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncternal Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $86,281.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.20% of the stock of Oncternal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.05% of the stock of Oncternal Therapeutics is held by institutions.Read more about Oncternal Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Oncternal Therapeutics are expected to grow in the coming year, from ($10.78) to ($10.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncternal Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncternal Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncternal Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Oncternal Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Oncternal Therapeutics Stock (NASDAQ:ONCT)Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Read More ONCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONCT Stock News HeadlinesJune 5 at 3:30 AM | americanbankingnews.comOncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.comMay 31, 2024 | americanbankingnews.comOncternal Therapeutics (NASDAQ:ONCT) Stock Rating Reaffirmed by HC WainwrightMay 30, 2024 | globenewswire.comOncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerMay 28, 2024 | americanbankingnews.comOncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews.comMay 11, 2024 | msn.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 Oncternal Therapeutics Inc Earnings CallMay 9, 2024 | msn.comONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | sfgate.comOncternal Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comOncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsMay 8, 2024 | markets.businessinsider.comOncternal Therapeutics earnings: here's what Wall Street expectsMay 7, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)May 2, 2024 | globenewswire.comOncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial ResultsMay 1, 2024 | globenewswire.comOncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)April 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Addus Homecare (ADUS)April 19, 2024 | uk.finance.yahoo.comEwing Sarcoma Drug Pipeline Market Research 2024: Insights About 25+ Companies and 25+ Pipeline DrugsApril 18, 2024 | globenewswire.comOncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerApril 17, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)April 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Oncternal Therapeutics with Adjusted Price Target Amid Positive Financials and Upcoming CatalystsApril 14, 2024 | insidermonkey.com5 Buy-Rated Stocks with Latest Insider PurchasesApril 11, 2024 | finance.yahoo.comAIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USAMarch 15, 2024 | globenewswire.comOncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate CancerMarch 13, 2024 | markets.businessinsider.comNorthland Securities Keeps Their Buy Rating on Heron Therapeutics (HRTX)March 10, 2024 | finance.yahoo.comOncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 8, 2024 | finance.yahoo.comQ4 2023 Oncternal Therapeutics Inc Earnings CallMarch 8, 2024 | msn.comOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call TranscriptSee More Headlines Receive ONCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/07/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ONCT CUSIPN/A CIK1260990 Webwww.oncternal.com Phone(858) 434-1113Fax901-844-8075Employees27Year FoundedN/APrice Target and Rating Average Stock Price Target$28.33 High Stock Price Target$40.00 Low Stock Price Target$19.00 Potential Upside/Downside+233.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($12.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,480,000.00 Net Margins-3,160.73% Pretax Margin-3,160.73% Return on Equity-107.67% Return on Assets-91.04% Debt Debt-to-Equity RatioN/A Current Ratio4.66 Quick Ratio4.66 Sales & Book Value Annual Sales$790,000.00 Price / Sales31.85 Cash FlowN/A Price / Cash FlowN/A Book Value$10.19 per share Price / Book0.83Miscellaneous Outstanding Shares2,960,000Free Float2,628,000Market Cap$25.16 million OptionableOptionable Beta1.38 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. James B. Breitmeyer M.D. (Age 70)Ph.D., President, CEO & Director Comp: $881.36kMr. Richard G. Vincent CPA (Age 60)CFO & Treasurer Comp: $602.84kDr. Salim Yazji M.D. (Age 55)Chief Medical Officer Comp: $648.53kDr. Rajesh Krishnan Ph.D. (Age 51)Chief Technical & Scientific Officer Mr. Chase C. Leavitt (Age 42)General Counsel & Secretary Mr. Pablo UrbanejaSenior Vice President of Corporate DevelopmentMs. Anita WisethSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsTiziana Life SciencesNASDAQ:TLSAAllakosNASDAQ:ALLKAffimedNASDAQ:AFMDLifeVantageNASDAQ:LFVNBeyondSpringNASDAQ:BYSIView All CompetitorsInsiders & InstitutionsRichmond Brothers Inc.Sold 469,346 shares on 5/10/2024Ownership: 0.834%Quantum Private Wealth LLCBought 27,806 shares on 5/7/2024Ownership: 0.939%Robert James WillsBought 3,086 shares on 4/8/2024Total: $27,650.56 ($8.96/share)Robert James WillsBought 6,914 shares on 3/28/2024Total: $58,630.72 ($8.48/share)David F HaleBought 714 shares on 2/23/2024Total: $6,454.56 ($9.04/share)View All Insider TransactionsView All Institutional Transactions ONCT Stock Analysis - Frequently Asked Questions Should I buy or sell Oncternal Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncternal Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ONCT shares. View ONCT analyst ratings or view top-rated stocks. What is Oncternal Therapeutics' stock price target for 2024? 3 analysts have issued 12 month price targets for Oncternal Therapeutics' stock. Their ONCT share price targets range from $19.00 to $40.00. On average, they anticipate the company's stock price to reach $28.33 in the next twelve months. This suggests a possible upside of 237.7% from the stock's current price. View analysts price targets for ONCT or view top-rated stocks among Wall Street analysts. How have ONCT shares performed in 2024? Oncternal Therapeutics' stock was trading at $10.7240 at the beginning of 2024. Since then, ONCT shares have decreased by 21.8% and is now trading at $8.39. View the best growth stocks for 2024 here. Are investors shorting Oncternal Therapeutics? Oncternal Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 23,100 shares, an increase of 77.7% from the April 30th total of 13,000 shares. Based on an average daily volume of 7,100 shares, the short-interest ratio is presently 3.3 days. Approximately 0.9% of the company's shares are short sold. View Oncternal Therapeutics' Short Interest. When is Oncternal Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ONCT earnings forecast. How were Oncternal Therapeutics' earnings last quarter? Oncternal Therapeutics, Inc. (NASDAQ:ONCT) announced its earnings results on Thursday, May, 9th. The company reported ($2.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.88) by $0.05. The business earned $0.57 million during the quarter, compared to analysts' expectations of $0.18 million. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative trailing twelve-month return on equity of 107.67%. During the same period in the prior year, the company earned ($4.00) EPS. When did Oncternal Therapeutics' stock split? Oncternal Therapeutics's stock reverse split on the morning of Monday, January 8th 2024. The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Oncternal Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncternal Therapeutics investors own include Overstock.com (OSTK), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Avadel Pharmaceuticals (AVDL), Aldeyra Therapeutics (ALDX), Boeing (BA), CASI Pharmaceuticals (CASI) and Dynavax Technologies (DVAX). Who are Oncternal Therapeutics' major shareholders? Oncternal Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Quantum Private Wealth LLC (0.94%) and Richmond Brothers Inc. (0.83%). Insiders that own company stock include Chase C Leavitt, Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent, Robert James Wills and Salim Yazji. View institutional ownership trends. How do I buy shares of Oncternal Therapeutics? Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ONCT) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.